Medindia

X

Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report

Thursday, September 17, 2009 General News J E 4
Advertisement
NEW YORK, Sept. 3 Reportlinker.com announces that a new market research report is available in its catalogue.

Therapeutics for Memory and Cognition Disorders

http://www.reportlinker.com/p0118583/Therapeutics-for-Memory-and-Cognition-Disorders.html

This Report:

Chapter-1: SUMMARY

SUMMARY TABLE WORLDWIDE POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, BY DISEASE AREA, THROUGH 2014 ($ MILLIONS) 4

SUMMARY FIGURE WORLDWIDE MEMORY/COGNITION THERAPEUTICS MARKET, BY DISEASE AREA, 2008 (%) 5

DISEASE STATES 6

DISEASE STATES (CONTINUED) 7

TREATMENTS IN DEVELOPMENT 8

THE FUTURE 9

Chapter-2: OVERVIEW

DEFINITION AND MARKET STRUCTURE 10

WHAT IS COGNITION? 10

COMPONENT SYSTEMS 11

Working Memory 11

Knowledge Base (Long-term Memory) 11

Executive System 12

Response System 12

COMPONENT PROCESSES 13

Attention 13

Perception 13

Memory and Learning 13

Organization 13

Reasoning and Problem Solving 14

COGNITION VERSUS MEMORY 14

HOW ARE COGNITION AND MEMORY MEASURED? 15

TABLE 1 DIAGNOSTIC TESTS 15

TABLE 1 (CONTINUED) 16

THE CHALLENGE 17

MAIN DISEASE AREAS 18

MARKET SIZE AND KEY PLAYERS 18

TABLE 2 TOP COMPANIES WORKING IN MEMORY AND COGNITION AND ASSOCIATED WORLDWIDE MARKET SHARE (%) 19

HISTORY 19

FUTURE DEVELOPMENT 19

Chapter-3: APPLICATIONS

PRIMARY 20

TABLE 3 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 20

FIGURE 1 DEMENTIA CASES BY UNDERLYING DISEASE STATE (%) 21

SECONDARY 22

MEDICATION-RELATED 22

SUBSTANCE ABUSE 23

CREUTZFELDT JAKOB DISEASE 23

Creutzfeldt Jakob Disease (Continued) 24

ADHD 25

MULTIPLE SCLEROSIS 25

Multiple Sclerosis (Continued) 26

INFECTION 27

METABOLIC DISORDERS 27

BRAIN TUMORS 28

CABG 28

TABLE 4 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 28

PRIMARY 28

ALZHEIMER'S DISEASE 28

TABLE 5 WORLDWIDE DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%) 29

TABLE 6 EXISTING TREATMENTS: ALZHEIMER'S DISEASE 29

Role of the Cholinergic System 29

Role of Beta-Amyloid Protein 30

TABLE 7 TREATMENT FORECAST FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS) 31

FIGURE 2 TREATMENT FORECAST FOR ALZHEIMER'S DISEASE, 2007-2014 ($ MILLIONS) 31

VASCULAR DEMENTIA 32

TABLE 8 WORLDWIDE DISEASE PREVALENCE: VASCULAR DEMENTIA (%) 32

TABLE 9 EXISTING TREATMENTS: VASCULAR DEMENTIA 32

Cause 33

VCIND 34

Binswanger's Disease 34

Multi-Infarct Dementia 34

Treatment 35

TABLE 10 TREATMENT FORECAST FOR VASCULAR DEMENTIA, THROUGH 2014 ($ MILLIONS) 35

FIGURE 3 TREATMENT FORECAST FOR VASCULAR DEMENTIA, 2007-2014 ($ MILLIONS) 36

Counseling and Psychotherapy 37

Pharmacotherapy 37

Outlook 38

LEWY BODY DEMENTIA 38

TABLE 11 WORLDWIDE DISEASE PREVALENCE: LEWY BODY DEMENTIA (%) 39

Treatment 39

TABLE 12 EXISTING TREATMENTS: LBD 40

Outlook 40

TABLE 13 TREATMENT FORECAST FOR LBD, THROUGH 2014 ($ MILLIONS) 40

FIGURE 4 TREATMENT FORECAST FOR LBD, 2007-2014 ($ MILLIONS) 41

PARKINSON'S DISEASE 41

Parkinson's Disease (Continued) 42

Other Parkinsonism Syndromes 43

Recognizing Other Causes of Parkinsonism 43

Medication-Induced Parkinsonism 44

Corticobasal Degeneration (CBD) 44

Multiple System Atrophy (MSA) 44

Multiple System Atrophy (Continued) 45

Multiple System Atrophy (Continued) 46

SCHIZOPHRENIA 47

Schizophrenia (Continued) 48

Schizophrenia (Continued) 49

TABLE 14 WORLDWIDE DISEASE PREVALENCE: SCHIZOPHRENIA (%) 50

Treatment 50

TABLE 15 EXISTING TREATMENTS: SCHIZOPHRENIA 51

TABLE 16 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), THROUGH 2014 ($ MILLIONS) 51

FIGURE 5 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS), 2007-2014 ($ MILLIONS) 52

Treatment (Continued) 53

Outlook 54

MCI/AAMI 54

TABLE 17 WORLDWIDE DISEASE PREVALENCE: MCI/AAMI (%) 55

TABLE 18 EXISTING TREATMENTS: MCI/AAMI 55

TABLE 19 TREATMENT FORECAST FOR MCI/AAMI, THROUGH 2014 ($ MILLIONS) 55

FIGURE 6 TREATMENT FORECAST FOR MCI/AAMI, 2007-2014 ($ MILLIONS) 56

HUNTINGTON'S DISEASE 56

Demographics 57

TABLE 20 WORLDWIDE DISEASE PREVALENCE: HUNTINGTON'S DISEASE (%) 57

TABLE 21 EXISTING TREATMENTS: HUNTINGTON'S DISEASE 57

Demographics (Continued) 58

Treatment 59

TABLE 22 TREATMENT FORECAST FOR HUNTINGTON'S DISEASE, THROUGH 2014 ($ MILLIONS) 60

FIGURE 7 TREATMENT FORECAST FOR HUNTINGTON'S DISEASE, 2007-2014 ($ MILLIONS) 61

HIV-RELATED MEMORY AND COGNITION EFFECTS 61

TABLE 23 WORLDWIDE DISEASE PREVALENCE: HIV-RELATED (%) 62

TABLE 24 EXISTING TREATMENTS: HIV-RELATED 63

TABLE 25 TREATMENT FORECAST FOR HIV-RELATED, THROUGH 2014 ($ MILLIONS) 63

FIGURE 8 TREATMENT FORECAST FOR HIV-RELATED, 2007-2014 ($ MILLIONS) 64

GENETIC DISEASES 64

TABLE 26 WORLDWIDE DISEASE PREVALENCE: GENETIC DISEASES (%) 64

TABLE 27 EXISTING TREATMENTS: GENETIC DISEASES 65

TABLE 28 TREATMENT FORECAST FOR GENETIC DISEASES: COGNITION ONLY, THROUGH 2014 ($ MILLION) 65

FIGURE 9 TREATMENT FORECAST FOR GENETIC DISEASES, 2007-2014 ($ MILLIONS) 66

Pick's Disease 66

Krabbe Disease 67

Krabbe Disease (Continued) 68

Chapter-4: MECHANISMS OF ACTION

MECHANISMS OF ACTION 69

TABLE 29 MARKETED TREATMENTS: ALL DISEASES 70

COMMON MECHANISMS 71

CHOLINESTERASE INHIBITORS 71

TABLE 30 CHOLINESTERASE INHIBITORS 71

NMDA Antagonists 71

TABLE 31 NMDA ANTAGONISTS 72

Nicotinics 72

TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 73

Calcineurins 73

TABLE 33 CALCINEURINS 73

GABA Modulators 74

TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 74

Hormones 75

TABLE 35 HORMONES 75

OTHER MECHANISMS 75

COGNITION ENHANCERS IN DEVELOPMENT 76

DRUGS FOR DISEASE MODIFICATION 76

Secretase Inhibitors 76

Metal Chelation 76

Vaccines 76

Statins 76

Neurotransmitter Targets 77

NSAIDS 77

Antioxidants 77

Hormones 78

Other Agents 78

TABLE 36 OVERVIEW OF MEMORY/COGNITION TREATMENTS 78

TABLE 36 (CONTINUED) 79

TABLE 37 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS, BY DEVELOPMENT STATUS 79

TABLE 37 (CONTINUED) 80

TABLE 37 (CONTINUED) 81

TABLE 37 (CONTINUED) 82

TABLE 37 (CONTINUED) 83

TABLE 37 (CONTINUED) 84

TABLE 37 (CONTINUED) 85

FIGURE 10 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL STAGE 85

Glutamate 86

Calcium Channels 86

Maxi-K Channels 86

CREB and Phosphodiesterase 87

Acetylcholine 87

Dopamine 87

Serotonin 88

GABA 88

The Cannabinoid System 88

Histamine 89

Neurohormones and Neuropeptides 89

Other Molecular Targets 89

Genome and Stem Cells 90

FUTURE COGNITION ENHANCERS 91

Changes in Society 91

Increasing Knowledge 91

Scientific Limitations 92

Implications 93

Potential Benefits and Harms 93

Health Economics 94

Regulation, Ethics, and Society 94

TABLE 38 OTC TREATMENTS/NATURAL PRODUCTS 95

OTC TREATMENTS 96

Ginkgo 97

GENE THERAPY 98

STIMULANTS 98

Stimulants (Continued) 99

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE

GROWTH DRIVERS 100

TABLE 39 TOP-SELLING MEMORY AND COGNITION DRUGS ($ MILLIONS) 100

AGING POPULATION 100

Aging Population (Continued) 101

OFF-LABEL USE 102

UNDERSTANDING OF MECHANISMS 103

Transcranial Magnetic Stimulation 104

Genetic Modifications 105

GROWTH OBSTACLES 105

UNDERSTANDING OF MECHANISMS 106

TABLE 40 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106

FIGURE 11 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106

CO-MORBID DISEASE STATES 107

ACCEPTANCE OF MEMORY AND COGNITION AS TREATABLE CONDITIONS 107

TREATMENT OF CHILDREN 107

Treatment of Children (Continued) 108

KEY COMPETITIVE FACTORS 109

PRODUCT LAUNCH 109

LIFE CYCLE MANAGEMENT 109

INDUSTRY LEADERS 110

MERCK 110

TABLE 41 MERCK MEMORY AND COGNITION PIPELINE 110

ROCHE 110

TABLE 42 ROCHE MEMORY AND COGNITION PIPELINE 110

PFIZER 111

TABLE 43 PFIZER MEMORY AND COGNITION PIPELINE 111

SHIRE 111

TABLE 44 SHIRE MEMORY AND COGNITION PIPELINE 111

CEPHALON 112

TABLE 45 CEPHALON MEMORY AND COGNITION PIPELINE 112

PAYORS 112

PAYORS (CONTINUED) 113

INTERNATIONAL ASPECTS 114

TABLE 46 PER CAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS) 115

BIOTECHNOLOGY CLUSTERS 116

LEGISLATION AND REGULATORY ENVIRONMENT 116

VALIDATED TARGETS 116

LACK OF BIOMARKERS 116

TRANSLATIONAL MEDICINE 117

REIMBURSEMENT 118

SCHEDULING STATUS 119

MEMORY AND COGNITION AS A STAND-ALONE INDICATION 119

RELATED DEALS AND PARTNERSHIPS 119

RELATED DEALS AND PARTNERSHIPS (CONTINUED) 120

TABLE 47 RELATED DEALS AND PARTNERSHIPS, 2002-2008 121

TABLE 47 (CONTINUED) 122

TABLE 47 (CONTINUED) 123

Chapter-6: PATENT ANALYSIS

INTRODUCTION 124

TRENDS BY COUNTRY 124

TABLE 48 PATENT ANALYSIS MAJOR U.S. PATENT HOLDERS IN MEMORY/COGNITION DISORDERS 124

FIGURE 12 MAJOR PATENT HOLDERS BY ASSIGNEE (%) 125

TRENDS BY ASSIGNEE 125

TRENDS BY TECHNOLOGY 126

TABLE 49 U.S. PATENT APPLICATIONS 127

TABLE 49 (CONTINUED) 128

TABLE 49 (CONTINUED) 129

TABLE 49 (CONTINUED) 130

TABLE 49 (CONTINUED) 131

TABLE 49 (CONTINUED) 132

TABLE 49 (CONTINUED) 133

TABLE 49 (CONTINUED) 134

TABLE 50 U.S. PATENTS GRANTED 135

TABLE 50 (CONTINUED) 136

TABLE 50 (CONTINUED) 137

TABLE 50 (CONTINUED) 138

TABLE 50 (CONTINUED) 139

TABLE 50 (CONTINUED) 140

TABLE 50 (CONTINUED) 141

TABLE 50 (CONTINUED) 142

Chapter-7: OUTLOOK: TRENDS AND CHALLENGES

GENERAL TRENDS 143

GENERAL TRENDS (CONTINUED) 144

ETHICAL IMPLICATIONS 145

ETHICAL IMPLICATIONS (CONTINUED) 146

Chapter-8: COMPANY PROFILES

ACADIA PHARMACEUTICALS 147

ACCERA, INC. 147

ACUMEN PHARMACEUTICALS 147

ALLON THERAPEUTICS (FKA NEURODISCOVERY) 147

ALZHYME PTY 148

AMARIN PHARMACEUTICALS 148

ASTRAZENECA 148

BRAINCELLS, INC. 149

COGNITION PHARMACEUTICALS 149

COLUCID PHARMACEUTICALS 149

COMENTIS 149

CORTEX PHARMACEUTICALS 150

ENVIVO PHARMACEUTICALS 150

GALENEA 150

GLAXOSMITH KLINE 151

HELICON THERAPEUTICS 151

INTELLECT NEUROSCIENCES 151

INTRA-CELLULAR THERAPIES 151

IPSEN 152

LEXICON PHARMACEUTICALS 152

MEDIVATION 152

MEMORY PHARMACEUTICALS 152

MERCK 153

MERCKSERONO 153

MITHRIDION 153

NEUREN PHARMACEUTICALS 153

NEUROSEARCH 153

NEURO-HITECH 154

NEWRON PHARMACEUTICALS 154

NOVARTIS 154

PFIZER 154

PRANA BIOTECHNOLOGY 155

PSYCHOGENICS 155

SANOFI-AVENTIS 155

SATORI PHARMACEUTICALS 155

SCIELE PHARMA 155

SEASIDE THERAPEUTICS 156

SHIRE 156

TAKEDA 156

TARGACEPT 156

TAURX THERAPEUTICS 156

TEVA PHARMACEUTICALS 157

VOYAGER PHARMACEUTICAL / DURAMED 157

WYETH 157

Chapter-9: APPENDIX

COMPANY LISTING 158

ACADIA PHARMACEUTICALS, INC. 158

ACCERA, INC. 158

ACUMEN PHARMACEUTICALS, INC. 158

ALLON THERAPEUTICS, INC. 159

ALZHYME, LTD. 159

AMARIN CORP PLC. 159

AMARIN PHARMA INC. 159

ASTRAZENECA 160

BRAINCELLS, INC. 160

COGNITION PHARMACEUTICALS LLC 160

COGNITIVE PHARMACEUTICALS LTD 160

COLUCID PHARMACEUTICALS 160

COMENTIS (FKA ATHENAGEN) 160

CORTEX PHARMACEUTICALS, INC. 15231 BARRANCA PARKWAY 161

ENVIVO PHARMACEUTICALS 161

GALENEA CORP. 161

GLAXOSMITHKLINE 161

HELICON THERAPEUTICS, INC. 161

INTELLECT NEUROSCIENCES, INC. 162

INTRA-CELLULAR THERAPIES 162

IPSEN 162

LEXICON PHARMACEUTICALS 162

MEDIVATION, INC. 163

MEMORY PHARMACEUTICALS 163

MERCK & CO., INC. 163

MERCKSERONO 163

MITHRIDION 163

NEUREN PHARMACEUTICALS, LTD 164

NEUROSEARCH A/S 164

NEURO-HITECH, INC. 164

NEWRON 164

NOVARTIS 165

PFIZER 165

PRANA 165

PSYCHOGENICS, INC. 165

SANOFI-AVENTIS 165

SATORI PHARMACEUTICALS 165

SCIELE PHARMA 166

SEASIDE THERAPEUTICS 166

SHIRE 166

TAKEDA 166

TARGACEPT, INC. 167

TAURX THERAPEUTICS LTD. 167

TEVA PHARMACEUTICALS 167

VOYAGER PHARMACEUTICALS 167

WYETH PHARMACEUTICALS 167

Wyeth Pharmaceuticals (Continued) 168

To order this report:

Therapeutics for Memory and Cognition Disorders

http://www.reportlinker.com/p0118583/Therapeutics-for-Memory-and-Cognition-Disorders.html

More market research reports here!

-- Details the disease states that lead to memory & cognition impairment -- Provides forecasts and detail relative to the products available to treat this condition. -- Provides definition and market structure, including discussion on cognition and diagnostic tests -- Analyzes market size and key players -- Identifies worldwide industry structure, including growth drivers and obstacles, and related technology considerations -- Details primary and secondary applications, legislation and the regulatory environment, related deals, and partnerships, patent analysis, and company profiles. -- Analyzes the market outlook, trends, and challenges.

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Healthcare Information Technolog...
S
Reportlinker Adds Anti-aging Products and Services...